Correspondence 0001213900-24-111138 from Cellyan Biotechnology Co., Ltd (HKPD)
Cellyan Biotechnology Co., Ltd
Date: Dec. 20, 2024 · CIK: 0002007702 · Accession: 0001213900-24-111138
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282876
Letter
Bancroft Capital, LLC
501 Office Center Drive, Suite 130
Fort Washington, PA 19034
December 20, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Trade & Services
100 F Street, N.E.
Washington, D.C. 20549
Attn: Nasreen Mohammed, and Suying Li
Re: Hong Kong Pharma Digital Technology Holdings Limited (CIK No. 0002007702)
Registration Statement on Form F-1, as amended (File No. 333-282876)
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), the undersigned, for itself and the other underwriters, hereby join in the request of Hong Kong Pharma Digital Technology Holdings Limited that the effective date of the above-referenced registration statement be accelerated so as to permit it to become effective at 4:30 p.m., Eastern Time, on December 20, 2024 or as soon thereafter as practicable.
Pursuant to 460 under the Act, we wish to advise you that the underwriters will distribute as many copies of the preliminary prospectus dated December 10, 2024 to underwriters, dealers, institutions and others as appears to be reasonable to secure adequate distribution of such preliminary prospectus.
The undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
Bancroft Capital, LLC
Show Raw Text
CORRESP
1
filename1.htm
Bancroft Capital, LLC
501 Office Center Drive, Suite 130
Fort Washington, PA 19034
December 20, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Trade & Services
100 F Street, N.E.
Washington, D.C. 20549
Attn: Nasreen Mohammed, and Suying Li
Re:
Hong Kong Pharma Digital Technology Holdings Limited (CIK No. 0002007702)
Registration Statement on Form F-1, as
amended (File No. 333-282876)
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
Pursuant to Rule 461 of
the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), the undersigned, for itself and
the other underwriters, hereby join in the request of Hong Kong Pharma Digital Technology Holdings Limited that the effective date of
the above-referenced registration statement be accelerated so as to permit it to become effective at 4:30 p.m., Eastern Time, on December
20, 2024 or as soon thereafter as practicable.
Pursuant to 460 under the
Act, we wish to advise you that the underwriters will distribute as many copies of the preliminary prospectus dated December 10, 2024
to underwriters, dealers, institutions and others as appears to be reasonable to secure adequate distribution of such preliminary prospectus.
The undersigned advises
that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
Bancroft Capital, LLC
By:
/s/ Jason Diamond
Name:
Jason Diamond
Title:
Head of Investment Banking